Current targeted therapies in the treatment of advanced colorectal cancer: a review

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment opt...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2016-07, Vol.8 (4), p.276-293
Main Authors: Moriarity, Andrew, O’Sullivan, Jacintha, Kennedy, John, Mehigan, Brian, McCormick, Paul
Format: Article
Language:English
Subjects:
Cancer
Carcinogenesis
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Metastases
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.
ISSN:1758-8340
1758-8359
1758-8359
DOI:10.1177/1758834016646734